Compare · BRTX vs CHNG
BRTX vs CHNG
Side-by-side comparison of BioRestorative Therapies Inc. (BRTX) and Change Healthcare Inc. (CHNG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRTX and CHNG operate in Managed Health Care (Health Care), so they compete in similar markets.
- CHNG is the larger of the two at $6.09B, about 660.3x BRTX ($9.2M).
- BRTX has hit the wire 3 times in the past 4 weeks while CHNG has been quiet.
- CHNG has more recent analyst coverage (5 ratings vs 1 for BRTX).
- Company
- BioRestorative Therapies Inc.
- Change Healthcare Inc.
- Price
- $0.38-6.83%
- $27.49+0.24%
- Market cap
- $9.2M
- $6.09B
- 1M return
- +63.76%
- -
- 1Y return
- -79.34%
- -
- Industry
- Managed Health Care
- Managed Health Care
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 3
- 0
- Recent ratings
- 1
- 5
BioRestorative Therapies Inc.
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate, which is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue (BAT). In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Change Healthcare Inc.
Change Healthcare Inc., an independent healthcare technology company, provides data and analytics-driven solutions to enhance clinical, financial, administrative, and patient engagement outcomes in the United States healthcare system. It operates through three segments: Software and Analytics, Network Solutions, and Technology-Enabled Services. The Software and Analytics segment offers software and analytics solutions for revenue cycle management, provider network management, payment accuracy, clinical decision support, value-based payment, consumer engagement, risk adjustment and quality performance, and imaging and clinical workflow. The Network Solutions segment provides solutions for financial, administrative, and clinical and pharmacy transactions; connected consumer health; intelligent healthcare network; electronic business-to-business and consumer-to-business payments; data; and aggregation and analytics of clinical and financial data. The Technology-Enabled Services segment offers solutions for financial and administrative management, value-based care, communication and payment, pharmacy benefits administration, and healthcare consulting. The company serves commercial insurers, private insurers, BlueCross Blue Shield plans, Medicare/Medicaid plans, provider-sponsored payers, third party administrators, emerging technology and data-driven health plans, and other specialty health benefits insurers, as well as hospitals and health systems, physician practices, dentists, pharmacies, skilled nursing facilities, home health agencies, telehealth providers, senior care facilities, laboratories, and other healthcare providers. Change Healthcare Inc. was incorporated in 2016 and is headquartered in Nashville, Tennessee.
Latest BRTX
- BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
- BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
- SEC Form 10-Q filed by BioRestorative Therapies Inc.
- BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
- BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
- BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 424B3 filed by BioRestorative Therapies Inc.
- BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
- SEC Form EFFECT filed by BioRestorative Therapies Inc.
Latest CHNG
- SEC Form SC 13G/A filed by Change Healthcare Inc. (Amendment)
- SEC Form 15-12G filed by Change Healthcare Inc.
- SEC Form SC 13D filed by Change Healthcare Inc.
- SEC Form 4: Rareshide Paul was granted 9,177 shares and returned $302,073 worth of shares to the company (49,968 units at $6.05), closing all direct ownership in the company
- SEC Form 4: Domenici Nella returned 29,280 shares to the company, closing all direct ownership in the company
- SEC Form 4: De Crescenzo Neil E. returned $15,274,411 worth of shares to the company (1,557,392 units at $9.81) and was granted 220,264 shares, closing all direct ownership in the company
- SEC Form 4: Laur Thomas was granted 45,888 shares and returned $1,808,577 worth of shares to the company (264,489 units at $6.84), closing all direct ownership in the company
- SEC Form 4: Pead Philip M returned $1,594,852 worth of shares to the company (102,642 units at $15.54), closing all direct ownership in the company
- SEC Form 4: Joshi Kriten returned $5,569,236 worth of shares to the company (569,000 units at $9.79) and was granted 45,888 shares, closing all direct ownership in the company
- SEC Form 4: Mckenzie Diana returned 40,706 shares to the company, closing all direct ownership in the company